AIM: To investigate the incidence and clinical outcome of Clostridium difficile (C. difficile) associated diarrhea (CDAD) in patients with hematologic disease. METHODS: We retrospectively reviewed the medical records of patients who underwent C. difficile testing in a tertiary hospital in 2011. The incidence and risk factors for CDAD and its clinical course including recurrence and mortality were assessed in patients with hematologic disease and compared with those in patients with nonhematologic disease. RESULTS: About 320 patients were diagnosed with CDAD (144 patients with hematologic disease; 176 with nonhematologic disease). The incidence of CDAD in patients with hematologic disease was estimated to be 36.7 cases/10000 patient hospital days, which was higher than the 5.4 cases/10000 patient hospital days in patients with nonhematologic disease. Recurrence of CDAD was more frequent in patients with hematologic disease compared to those with nonhematologic disease (18.8% vs 8.5%, P < 0.01), which was associated with higher re-use of causative antibiotics for CDAD. Mortality due to CDAD did not differ between the two groups. Multivariate analysis showed that intravenous immunoglobulin was the only significant factor associated with a lower rate of recurrence of CDAD in patients with hematologic disease. CONCLUSION: The incidence and recurrence of CDAD was higher in patients with hematologic disease than in those with nonhematologic disease.
AIM: To investigate the incidence and clinical outcome of Clostridium difficile (C. difficile) associated diarrhea (CDAD) in patients with hematologic disease. METHODS: We retrospectively reviewed the medical records of patients who underwent C. difficile testing in a tertiary hospital in 2011. The incidence and risk factors for CDAD and its clinical course including recurrence and mortality were assessed in patients with hematologic disease and compared with those in patients with nonhematologic disease. RESULTS: About 320 patients were diagnosed with CDAD (144 patients with hematologic disease; 176 with nonhematologic disease). The incidence of CDAD in patients with hematologic disease was estimated to be 36.7 cases/10000 patient hospital days, which was higher than the 5.4 cases/10000 patient hospital days in patients with nonhematologic disease. Recurrence of CDAD was more frequent in patients with hematologic disease compared to those with nonhematologic disease (18.8% vs 8.5%, P < 0.01), which was associated with higher re-use of causative antibiotics for CDAD. Mortality due to CDAD did not differ between the two groups. Multivariate analysis showed that intravenous immunoglobulin was the only significant factor associated with a lower rate of recurrence of CDAD in patients with hematologic disease. CONCLUSION: The incidence and recurrence of CDAD was higher in patients with hematologic disease than in those with nonhematologic disease.
Authors: Michel Warny; Jacques Pepin; Aiqi Fang; George Killgore; Angela Thompson; Jon Brazier; Eric Frost; L Clifford McDonald Journal: Lancet Date: 2005 Sep 24-30 Impact factor: 79.321
Authors: Michael S Wang; Charlesnika T Evans; Tulio Rodriguez; Dale N Gerding; Stuart Johnson Journal: Infect Control Hosp Epidemiol Date: 2012-12-18 Impact factor: 3.254
Authors: J Kim; J O Kang; H Kim; M-R Seo; T Y Choi; H Pai; E J Kuijper; I Sanders; W Fawley Journal: Clin Microbiol Infect Date: 2012-06-19 Impact factor: 8.067
Authors: M Gorschlüter; A Glasmacher; C Hahn; F Schakowski; C Ziske; E Molitor; G Marklein; T Sauerbruch; I G Schmidt-Wolf Journal: Clin Infect Dis Date: 2001-08-10 Impact factor: 9.079
Authors: Al B Benson; Jaffer A Ajani; Robert B Catalano; Constance Engelking; Steven M Kornblau; James A Martenson; Richard McCallum; Edith P Mitchell; Thomas M O'Dorisio; Everett E Vokes; Scott Wadler Journal: J Clin Oncol Date: 2004-07-15 Impact factor: 44.544
Authors: Yu Ling Lee-Tsai; Rodrigo Luna-Santiago; Roberta Demichelis-Gómez; Alfredo Ponce-de-León; Eric Ochoa-Hein; Karla María Tamez-Torres; María T Bourlon; Christianne Bourlon Journal: Blood Res Date: 2019-06-25